STUDIO

SynAct

SynAct Pharma summarises busy second quarter

SynAct Pharma's CEO Jeppe Øvlesen and CFO Patrik Renblad visit BioStock's studio to talk about the second quarter report, the uplisting to Nasdaq Stockholm...

BioInvent and CASI on their collaboration

BioStock intervjuar Abliavs vd Ellen Donnelly via link

Abliva on the 200 MSEK financing round

Sara Mangsbo Ultimovacs

An in-depth look at Ultimovacs’ cancer vaccine

BioStock Studio: Expres2ion’s CEO gives status update

Load more

RECOMMENDED READING

Aptahem increasingly close to clinical studies

BioStock reached out to Malmö company Aptahem, which is developing an emergency treatment for...

BioStock Investor Meeting, September 14

On September 14, we will arrange the next BioStock Investor Meeting, where life science...
Patent Promore Pharma

Promore Pharma strengthens IP-protection

BioStock Life sicence autum summit november 2022

BioStock Life Science Summit 2022

Abliva new approach to mitochondrial diseases

A new approach to mitochondrial diseases

Lipum has wind in its sails for phase I

Lipum has wind in its sails for phase I

EVENT

© BioStock 2022